Depression SymptomsMirror JournalNCT07126275
Mirror Journaling App Study
A study testing Mirror App Journaling and Mood Tracking Study in people with Depression Symptoms and Anxiety Symptoms, run by Child Mind Institute at 1 site in United States.
Trial summary
This study has three primary aims: 1) Validate Mirror's Mood Check feature by measuring convergent validity;2) Assess user experience and acceptability metrics (e.g., usability, engagement, satisfaction) of the Mirror app, with a particular focus on the journaling feature; 3) Assess the impact of guided journaling and… Read more about this study
- Who is it for?
- Ages 18 to 25 yearsHealthy volunteers can take part
- Conditions the study is for
- Depression Symptoms, Anxiety Symptoms
- What is being tested?
- Mirror App Journaling and Mood Tracking Study
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 500 participants
- Where
- 1 siteUnited States
- Study dates
- 12 Mar 2025to Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 25 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Prolific users ages 18-25
- Must reside in the U.S.
- Must have access to a smart device, and are willing to download an external app (screened by Prolific Academic)
- Must complete screening form which consists of the Patient Health Questionnaire (PHQ-2) and the Generalized Anxiety Disorder (GAD-7) Scale.
- Must have mild to moderate depressive or anxiety symptoms, as measured by the screening form
Who cannot join
- None
Trial locations and contacts
1 site in 1 country.
About this study
This study has three primary aims: 1) Validate Mirror's Mood Check feature by measuring convergent validity;2) Assess user experience and acceptability metrics (e.g., usability, engagement, satisfaction) of the Mirror app, with a particular focus on the journaling feature; 3) Assess the impact of guided journaling and mood tracking on depressive and anxious symptoms.
Read the detailed description
BACKGROUND AND SIGNIFICANCE
Depression is a common and serious mental disorder that can negatively affect an individual's thoughts, feelings, and ability to perform daily activities. The onset of depression can occur at any stage of life. The estimated prevalence of depression in childhood is low (1.09%) and the highest in young adulthood (21%) , with a sharp increase seen during adolescence . In 2022, 15.08% of adolescents between the ages of 12 and 17 reported suffering from at least one major depressive episode in the past year. Of those, only 27.2% received consistent treatment. Depression in adolescents, particularly if left untreated, is associated with negative consequences later in life, such as higher levels of substance use disorders, worse health and social functioning, less educational and financial achievement, and increased criminality. Considering these serious and lasting consequences, depression in adolescents is a significant public health issue that deserves proactive approaches to prevent or mitigate its negative impact on individuals and society.
Journaling is recognized as a common, non-pharmacological tool in the management of mental disorders, including depression. Journaling can promote self-reflection and self-awareness, which can help improve mental health (e.g., enhance emotional regulation, reduce stress, facilitate behavioral changes). Although digital journaling can offer equivalent expression and release as traditional journaling with pen and paper, digital journaling has many advantages, such as enhanced accessibility, data organization, data security, analytic potential, and multimedia integration; these features make digital journaling a highly efficient tool for managing mental health. As such, a growing body of research supports the clinical benefits of digital journaling for depression in adults. Yet, the acceptability and efficacy of digital journaling in adolescents are understudied, calling for further investigation.
Mirror is a mobile journaling app developed by the Child Mind Institute (CMI) for youth who want to explore and improve their mental health, particularly addressing symptoms related to depression. Like other mobile journaling apps, the Mirror app enables users to express their thoughts and emotions through multimodal entries (i.e., written, voice, selfie video) and provides prompts to facilitate journal entries. However, the Mirror app offers unique, emotionally supportive features to help users identify and process emotions. First, Mirror users can explore multimodal guided journaling (e.g., video, audio, and written entries with guided prompts); as the app's name suggests, one of the guides encourages users to stand in front of a mirror and start video journaling while making eye contact with themselves. This guided journaling using a mirror can help increase users' self-reflection and self-expression. Second, the Mirror app has a user-centered mood-checking feature ("Mood Check") designed based on the circumplex model of emotions, in which the x- and y-axis represent pleasantness and energy level, respectively. Mirror's Mood Check feature is visually appealing (i.e., two sliders corresponding to the two axes) and allows users to gain more granular insights into their emotional states.
With these unique and user-centered features described above, the Mirror app has great potential for increasing adolescent users' engagement, which could significantly influence the efficacy of digital journaling on mental health. Importantly, the information gained from the proposed study will guide the development of future clinical trials for adolescents suffering from depression.
PROPOSED STUDY
This study has three primary aims: 1) Validate Mirror's Mood Check feature by measuring convergent validity;2) Assess user experience and acceptability metrics (e.g., usability, engagement, satisfaction) of the Mirror app, with a particular focus on the journaling feature; 3) Assess the impact of guided journaling and mood tracking on depressive and anxious symptoms.
This study will enroll 500 young adults ages 18-25 via Prolific Academic (https://www.prolific.com/) an online research participant recruitment tool.
Users on Prolific Academic must be the age of majority in the locality in which they register for an account. Prolific users ages 18-25 that reside in the U.S., have access to a smart device, and are willing to download an external app (screened by Prolific Academic), will be eligible to complete a screening form. Participants with mild to moderate depressive or anxiety symptoms will be eligible to enroll in the study.
Participants on Prolific will complete a baseline assessment and will then be randomized to complete one of four study conditions over the course of 8 weeks:
- Guided Journaling + Mood Tracking: Structured prompts and regular feedback to facilitate journaling, alongside daily mood tracking.
- Unguided Journaling + Mood Tracking: Free-form journaling with access to mood tracking tools without additional guidance.
- Mood Tracking Only: Mood tracking tools without any journaling component.
- Control Group: Information on mental health resources without journaling or mood tracking.
In addition to their journaling and mood check assignments, all participants will also complete a weekly check in questionnaire, post-study and one month follow up assessment of symptoms and user satisfaction with the app.
- Conditions
- Depression Symptoms, Anxiety Symptoms
- Being tested
- Mirror App Journaling and Mood Tracking Study
- Medical subject headings
- Depression, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mirror App Journaling and Mood Tracking StudyDevice
Mirror is a mobile journaling app developed by the Child Mind Institute (CMI) for youth who want to explore and improve their mental health, particularly addressing symptoms related to depression. The Mirror app enables users to express their thoughts and emotions through multimodal entries (i.e., written, voice, selfie video) and provides prompts to facilitate journal entries using unique, emotionally supportive features to help users identify and process emotions. Users can also complete free-form, unguided journaling, and can complete daily mood tracking and see changes/progress over time.
| Study group | Role | What they receive |
|---|---|---|
| Mirror Guided Journaling + Mood Tracking | Experimental | Structured prompts and regular feedback to facilitate journaling, alongside daily mood tracking in the Mirror App. Receives: Device: Mirror App Journaling and Mood Tracking Study |
| Mirror Unguided Journaling + Mood Tracking | Experimental | Free-form journaling with access to daily mood tracking in the Mirror app without specific guided prompts. Receives: Device: Mirror App Journaling and Mood Tracking Study |
| Mirror Mood Tracking Only | Experimental | Daily mood tracking in the Mirror app, without any journaling component. Receives: Device: Mirror App Journaling and Mood Tracking Study |
| Control Group | No intervention | Information on mental health resources without journaling or mood tracking. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Depressive Symptoms
Statistical models including ANOVA and regression will be used to compare changes in depressive symptoms across the four groups. Changes in depressive symptoms will be assessed with the PROMIS Depression Short Form, which has scores that range from 8-40, with higher scores indicating greater depressive symptom severity. PROMIS was measured at baseline, post-intervention (8 weeks), and at a 1-month follow-up.
PHQ-8 was administered at baseline as a screening instrument to determine eligibility and was also administered at the 8-week assessment. PHQ-8 was not administered at the 1-month follow-up.
This record update corrects an administrative error in the original ClinicalTrials.gov registration, which listed PHQ-8 and GAD-7 as primary outcomes and omitted the PROMIS measures. The IRB-approved protocol dated February 10, 2025, prior to study initiation, specified PROMIS and WHODAS as outcome measures. This update aligns the registration record with the approved protocol.
Measured: 12 weeks (including 1 month follow up)
Anxiety Symptoms
Statistical models including ANOVA and regression will be used to compare changes in anxiety symptoms across the four groups. Changes in anxiety symptoms will be assessed with the PROMIS Anxiety Short Form, which has scores that range from 7-35, with higher scores indicating greater anxiety symptom severity. PROMIS was measured at baseline, post-intervention (8 weeks), and at a 1-month follow-up.
GAD-7 was administered at baseline as a screening instrument to determine eligibility and was also administered at the 8-week assessment. GAD-7 was not administered at the 1-month follow-up.
This record update corrects an administrative error in the original ClinicalTrials.gov registration, which listed PHQ-8 and GAD-7 as primary outcomes and omitted the PROMIS measures. The IRB-approved protocol dated February 10, 2025, prior to study initiation, specified PROMIS and WHODAS as outcome measures. This update aligns the registration record with the approved protocol.
Measured: 12 weeks (including 1 month follow up)
Impairment
Statistical models including ANOVA and regression will be used to compare changes in impairment across the four groups. Changes in impairment will be assessed with the WHO Disability Assessment Schedule (WHODAS 2.0), which has scores that range from 0-100 with higher scores indicating higher levels of impairment.
Impairment will be measured at baseline, post 8-weeks of the intervention, and at a 1 month follow up.
Measured: 12 weeks (including 1 month follow up)
Secondary outcomes (3)
User Experience
User experience data will also be collected and analyzed to support product improvement. Data will be collected with the The MAUQ, or mHealth App Usability Questionnaire, a tool used to assess the usability of mobile health (mHealth) applications. It provides a structured way to gather user feedback and determine how easy and useful an app is for its intended purpose using likert scale questions.
Measured: 8 weeks
User Experience
User experience data will be collected and analyzed to support product improvement. Data will be collected with the System Usability Scale (SUS), a ten-item Likert scale giving a global view of subjective assessments of usability, which generates a score from 0-100 with higher scores indicating higher levels of usability.
Measured: 8 weeks
User Feedback
User experience data will be collected and analyzed to support product improvement. Data will be collected with a feedback questionnaire developed by the Child Mind Institute that asks questions specifically about the Mirror platform. The assessment includes both close and open ended questionnaires.
Measured: 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2025
- Study start12 Mar 2025
- Primary completion15 Jul 2025
- Study completionAug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Depression SymptomsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Child Mind Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Michael Milham, MD, PhD, Principal investigator, Child Mind Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07126275
- Sponsor's protocol ID
- Pro00080718
- Acronym
- Mirror Journal
- Status last verified
- Mar 2026
- First submitted
- 11 Feb 2025
- Last updated
- 10 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mirror Journaling App Study
- ClinicalTrials.gov ID
- NCT07126275
- Acronym / sponsor ID
- Mirror Journal / Pro00080718
- Conditions
- Depression Symptoms, Anxiety Symptoms
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Child Mind InstituteUniversity, hospital or other
- Study start
- 12 Mar 2025 (actual)
- Primary completion
- 15 Jul 2025 (actual)
- Study completion
- Aug 2026 (estimated)
- First posted
- 17 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study has three primary aims: 1) Validate Mirror's Mood Check feature by measuring convergent validity;2) Assess user experience and acceptability metrics (e.g., usability, engagement, satisfaction) of the Mirror app, with a particular focus on the journaling feature; 3) Assess the impact of guided journaling and mood tracking on depressive and anxious symptoms.
Detailed description
BACKGROUND AND SIGNIFICANCE
Depression is a common and serious mental disorder that can negatively affect an individual's thoughts, feelings, and ability to perform daily activities. The onset of depression can occur at any stage of life. The estimated prevalence of depression in childhood is low (1.09%) and the highest in young adulthood (21%) , with a sharp increase seen during adolescence . In 2022, 15.08% of adolescents between the ages of 12 and 17 reported suffering from at least one major depressive episode in the past year. Of those, only 27.2% received consistent treatment. Depression in adolescents, particularly if left untreated, is associated with negative consequences later in life, such as higher levels of substance use disorders, worse health and social functioning, less educational and financial achievement, and increased criminality. Considering these serious and lasting consequences, depression in adolescents is a significant public health issue that deserves proactive approaches to prevent or mitigate its negative impact on individuals and society.
Journaling is recognized as a common, non-pharmacological tool in the management of mental disorders, including depression. Journaling can promote self-reflection and self-awareness, which can help improve mental health (e.g., enhance emotional regulation, reduce stress, facilitate behavioral changes). Although digital journaling can offer equivalent expression and release as traditional journaling with pen and paper, digital journaling has many advantages, such as enhanced accessibility, data organization, data security, analytic potential, and multimedia integration; these features make digital journaling a highly efficient tool for managing mental health. As such, a growing body of research supports the clinical benefits of digital journaling for depression in adults. Yet, the acceptability and efficacy of digital journaling in adolescents are understudied, calling for further investigation.
Mirror is a mobile journaling app developed by the Child Mind Institute (CMI) for youth who want to explore and improve their mental health, particularly addressing symptoms related to depression. Like other mobile journaling apps, the Mirror app enables users to express their thoughts and emotions through multimodal entries (i.e., written, voice, selfie video) and provides prompts to facilitate journal entries. However, the Mirror app offers unique, emotionally supportive features to help users identify and process emotions. First, Mirror users can explore multimodal guided journaling (e.g., video, audio, and written entries with guided prompts); as the app's name suggests, one of the guides encourages users to stand in front of a mirror and start video journaling while making eye contact with themselves. This guided journaling using a mirror can help increase users' self-reflection and self-expression. Second, the Mirror app has a user-centered mood-checking feature ("Mood Check") designed based on the circumplex model of emotions, in which the x- and y-axis represent pleasantness and energy level, respectively. Mirror's Mood Check feature is visually appealing (i.e., two sliders corresponding to the two axes) and allows users to gain more granular insights into their emotional states.
With these unique and user-centered features described above, the Mirror app has great potential for increasing adolescent users' engagement, which could significantly influence the efficacy of digital journaling on mental health. Importantly, the information gained from the proposed study will guide the development of future clinical trials for adolescents suffering from depression.
PROPOSED STUDY
This study has three primary aims: 1) Validate Mirror's Mood Check feature by measuring convergent validity;2) Assess user experience and acceptability metrics (e.g., usability, engagement, satisfaction) of the Mirror app, with a particular focus on the journaling feature; 3) Assess the impact of guided journaling and mood tracking on depressive and anxious symptoms.
This study will enroll 500 young adults ages 18-25 via Prolific Academic (https://www.prolific.com/) an online research participant recruitment tool.
Users on Prolific Academic must be the age of majority in the locality in which they register for an account. Prolific users ages 18-25 that reside in the U.S., have access to a smart device, and are willing to download an external app (screened by Prolific Academic), will be eligible to complete a screening form. Participants with mild to moderate depressive or anxiety symptoms will be eligible to enroll in the study.
Participants on Prolific will complete a baseline assessment and will then be randomized to complete one of four study conditions over the course of 8 weeks:
- Guided Journaling + Mood Tracking: Structured prompts and regular feedback to facilitate journaling, alongside daily mood tracking.
- Unguided Journaling + Mood Tracking: Free-form journaling with access to mood tracking tools without additional guidance.
- Mood Tracking Only: Mood tracking tools without any journaling component.
- Control Group: Information on mental health resources without journaling or mood tracking.
In addition to their journaling and mood check assignments, all participants will also complete a weekly check in questionnaire, post-study and one month follow up assessment of symptoms and user satisfaction with the app.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Mirror Guided Journaling + Mood Tracking | Experimental | Device: Mirror App Journaling and Mood Tracking StudyStructured prompts and regular feedback to facilitate journaling, alongside daily mood tracking in the Mirror App. |
| Mirror Unguided Journaling + Mood Tracking | Experimental | Device: Mirror App Journaling and Mood Tracking StudyFree-form journaling with access to daily mood tracking in the Mirror app without specific guided prompts. |
| Mirror Mood Tracking Only | Experimental | Device: Mirror App Journaling and Mood Tracking StudyDaily mood tracking in the Mirror app, without any journaling component. |
| Control Group | No intervention | –Information on mental health resources without journaling or mood tracking. |
Who may qualify
- Ages
- 18 to 25 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Prolific users ages 18-25
- Must reside in the U.S.
- Must have access to a smart device, and are willing to download an external app (screened by Prolific Academic)
- Must complete screening form which consists of the Patient Health Questionnaire (PHQ-2) and the Generalized Anxiety Disorder (GAD-7) Scale.
- Must have mild to moderate depressive or anxiety symptoms, as measured by the screening form
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mirror App Journaling and Mood Tracking StudyMirror is a mobile journaling app developed by the Child Mind Institute (CMI) for youth who want to explore and improve their mental health, particularly addressing symptoms related to depression. The Mirror app enables users to express their thoughts and emotions through multimodal entries (i.e., written, voice, selfie video) and provides prompts to facilitate journal entries using unique, emotionally supportive features to help users identify and process emotions. Users can also complete free-form, unguided journaling, and can complete daily mood tracking and see changes/progress over time. | Device | Mirror Guided Journaling + Mood Tracking, Mirror Mood Tracking Only, Mirror Unguided Journaling + Mood Tracking |
Primary outcome
Depressive Symptoms
Time frame: 12 weeks (including 1 month follow up)
Statistical models including ANOVA and regression will be used to compare changes in depressive symptoms across the four groups. Changes in depressive symptoms will be assessed with the PROMIS Depression Short Form, which has scores that range from 8-40, with higher scores indicating greater depressive symptom severity. PROMIS was measured at baseline, post-intervention (8 weeks), and at a 1-month follow-up. PHQ-8 was administered at baseline as a screening instrument to determine eligibility and was also administered at the 8-week assessment. PHQ-8 was not administered at the 1-month follow-up. This record update corrects an administrative error in the original ClinicalTrials.gov registration, which listed PHQ-8 and GAD-7 as primary outcomes and omitted the PROMIS measures. The IRB-approved protocol dated February 10, 2025, prior to study initiation, specified PROMIS and WHODAS as outcome measures. This update aligns the registration record with the approved protocol.
Anxiety Symptoms
Time frame: 12 weeks (including 1 month follow up)
Statistical models including ANOVA and regression will be used to compare changes in anxiety symptoms across the four groups. Changes in anxiety symptoms will be assessed with the PROMIS Anxiety Short Form, which has scores that range from 7-35, with higher scores indicating greater anxiety symptom severity. PROMIS was measured at baseline, post-intervention (8 weeks), and at a 1-month follow-up. GAD-7 was administered at baseline as a screening instrument to determine eligibility and was also administered at the 8-week assessment. GAD-7 was not administered at the 1-month follow-up. This record update corrects an administrative error in the original ClinicalTrials.gov registration, which listed PHQ-8 and GAD-7 as primary outcomes and omitted the PROMIS measures. The IRB-approved protocol dated February 10, 2025, prior to study initiation, specified PROMIS and WHODAS as outcome measures. This update aligns the registration record with the approved protocol.
Impairment
Time frame: 12 weeks (including 1 month follow up)
Statistical models including ANOVA and regression will be used to compare changes in impairment across the four groups. Changes in impairment will be assessed with the WHO Disability Assessment Schedule (WHODAS 2.0), which has scores that range from 0-100 with higher scores indicating higher levels of impairment. Impairment will be measured at baseline, post 8-weeks of the intervention, and at a 1 month follow up.
3 secondary outcomes
User Experience
Time frame: 8 weeks
User Experience
Time frame: 8 weeks
User Feedback
Time frame: 8 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Depression Symptoms
Not yet recruiting
Examining the Effectiveness of a Brief Therapeutic Intervention for Reducing Self-Harm Among Adolescents
Self Injurious Behavior, Self Injurious Behavior Without Suicidal Intent
RecruitingPhase 3
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
Depressive Disorder, Major
Recruiting
Aquatic Exercise in Patients With Knee Osteoarthritis
Central Sensitization, Knee Osteoarthristis
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Depressive Disorder, Major
Recruiting
Single Session Personalized Aperiodic Transcranial Alternating Current Stimulation (PandA-tACS) for Antenatal Depression
Antenatal Depression
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael Milham, MD, PhD principal investigator
Child Mind Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mirror App Journaling and Mood Tracking Study in people with Depression Symptoms and Anxiety Symptoms, run by Child Mind Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 10 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Depressive Symptoms (time frame: 12 weeks (including 1 month follow up)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2026.